An expert resource for medical professionals
Provided FREE as a service to women’s health

The Alliance for
Global Women’s Medicine
A worldwide fellowship of health professionals working together to
promote, advocate for and enhance the Welfare of Women everywhere

An Educational Platform for FIGO

The Global Library of Women’s Medicine
Clinical guidance and resourses

A vast range of expert online resources. A FREE and entirely CHARITABLE site to support women’s healthcare professionals

The Global Academy of Women’s Medicine
Teaching, research and Diplomates Association

This chapter should be cited as follows:
Plante LA, Glob. libr. women's med.,
ISSN: 1756-2228; DOI 10.3843/GLOWM.409563

The Continuous Textbook of Women’s Medicine SeriesObstetrics Module

Volume 9

Principles and practice of obstetric high-dependency and critical care

Volume Editor: Professor Stephen Lapinsky, University of Toronto, Canada


Diagnosis and Management of Sepsis and Septic Shock in Pregnancy and the Puerperium

First published: February 2021

Study Assessment Option

By completing 4 multiple-choice questions (randomly selected) after studying this chapter readers can qualify for Continuing Professional Development awards from FIGO plus a Study Completion Certificate from GLOWM
See end of chapter for details


In October 2012, a healthy young woman, 17 weeks pregnant, went to a hospital in Ireland with a complaint of backache. Clinical examination suggested impending pregnancy loss, which was further borne out when, within 12 hours, membranes ruptured. She requested that delivery be effected, but the request was not honored, because the fetus was still alive, albeit weeks too early for extrauterine viability.

Sixty hours later, she was in septic shock.

Six days after admission, she was dead.1

Savita Halappanavar was not the only woman to die of obstetric sepsis in the year 2012, but she was one of the few whose name was widely known. The World Health Organization estimates that there are over 40,000 such deaths a year, worldwide,2 more than 99% of them in developing regions of the world. Early recognition and appropriately swift care have the potential to drive these numbers lower.


“There are known knowns: there are things we know we know. We also know there are known unknowns: that is to say we know there are some things we do not know. But there are also unknown unknowns – the ones we don’t know we don’t know … It is the latter category that tend to be the difficult ones.” (US Secretary of Defense Donald Rumsfeld, 2002)

The scientific understanding of sepsis is incomplete and continues to evolve. Interplay between pathogen and host is complex: the same microorganism that produces local infection in one individual can result in full-blown sepsis in another. This may be attributed to physiologic reserve, comorbidity, social behaviors, genetic determinants, host susceptibility, gene–environment interactions, pathogen–pathogen interactions, prevailing antimicrobial selection pressure, or other factors as yet unspecified.3

Sepsis is not synonymous with either bacteremia or infection, but should be understood as a matter of organ dysfunction which stems from a dysregulated host response to infection. Virtually any organ system can be affected: central nervous system (altered mental status); cardiovascular system (hypotension, myocardial dysfunction, or circulatory collapse); lungs (acute respiratory distress syndrome or ARDS; gastrointestinal system (paralytic ileus); liver (hepatic failure or abnormal transaminases); kidneys (oliguria or acute renal failure); hematologic system (thrombocytopenia or coagulopathy); and endocrine system (abnormal glucose handling, adrenal dysfunction.)

Our current understanding of sepsis pathophysiology includes roles for immune function (both innate and adaptive immunity), the microvascular circulation, the endothelium, and the gut, particularly its microbiome. Host and pathogen factors clearly affect both predisposition to, and recovery from, sepsis. In addition, host–pathogen communication modifies or mediates development of sepsis.

The innate immune system of humans, like that of other mammals, contains pattern-recognition receptors (PRRs), the best known of which are Toll-like receptors (TLRs.) PRRs are keyed to identify molecular motifs known as pathogen-associated molecular patterns (PAMPs), which are absent in higher organisms but expressed by pathogens; these include lipopolysaccharides, components of bacterial cell walls, and bacterial DNA.4 PRRs also recognize the host’s own danger-associated molecular patterns (DAMPs), also known as alarmins, such as heat shock proteins, fibrinogen, and high-mobility group box-1 protein (HMGB1), which are released by stressed or dead cells.4,5,6,7 In response to PAMPs or alarmins, PRRs release a variety of inflammatory signals which are packaged into molecular complexes known as inflammasomes. Activated inflammasomes produce a series of proinflammatory responses, such as upregulating genes that code for cytokines, mediating the release of interleukins, and initiation of apoptosis. In concert with the proinflammatory response, the challenged host must also activate a systemic anti-inflammatory response, which includes epigenetic modification, immune cell regulation, interference with TLR signaling, and a vagally mediated cholinergic pathway.4,5,7 A successful host response must balance pro-inflammatory and anti-inflammatory limbs in order to clear pathogens without destroying the host’s own tissues and organs.

Pathogen virulence varies in many ways, some of which are affected by host characteristics. For example, molecules produced by a stressed or compromised host are identified by a bacterial quorum sensing system, which then preferentially turns on replication and virulence genes.5 Genetic differences play a role in infection and sepsis beyond the obvious factors of age or comorbidities; specific polymorphisms in cytokine and TLR genes have been identified which increase susceptibility to various pathogens, and other polymorphisms in IL-8, protein C, and others increase the risk of organ failure and mortality when infection or sepsis is present.8

Disrupted endothelial integrity is a hallmark of sepsis, and barrier failure is mediated by HMBG1, among other DAMPs.7 Dysfunctional vascular endothelium predisposes to coagulopathy via effects on tissue factor, thrombin generation, and fibrinolysis.9 Mitochondrial dysfunction, failure of intercellular communication, and impaired cellular bioenergetics impede organ function.7

Prevailing concepts of pregnancy as an immunodeficient or immunoprivileged state are simplistic and may be incorrect.10,11 While immune cells in the maternal decidua are altered so as to maintain tolerance of fetal and paternal antigens, this does not translate into a general immuno-incompetence. In fact, pregnancy does not affect B-cell numbers, T-cell numbers, subsets or function, complement, antibody-dependent cellular cytotoxicity, or levels of IgA, IgG or IgM.12 However, trophoblast may regulate maternal immune cells in their development, differentiation, or function11 and the placenta is known to harbor its own microbiome, which, oddly, resembles the oral microbiome.13 It is probably safe to say that as little as we understand about sepsis generally, we understand even less about sepsis in pregnancy.


Terminology related to sepsis has changed in recent years. When reading medical literature, keep in mind that the authors’ definitions may not be those used in current practice. Infection is not synonymous with sepsis. Neither bacteremia nor the outdated term septicemia should be used interchangeably with the term sepsis, though the medical literature on obstetric sepsis often looks at bacteremia instead (see Box 1 for definitions). A significant problem underlying the definition of sepsis is the absence of a clear diagnostic marker: sepsis is currently understood as a clinical syndrome of “physiologic, pathologic, and biochemical abnormalities induced by infection.”14

Box 1 Definitions

Infection: “microbial phenomenon characterized by inflammatory response to the presence of microorganisms or the invasion of normal sterile host tissue by those organisms”15

Inflammation: a host response to infection, characterized by local signs (erythema, warmth, tenderness, swelling, loss of function) and/or systemic signs (vasodilation, fever, confusion, discomfort, edema, increased capillary leak, organ dysfunction)72

Bacteremia: the presence of live bacteria in the bloodstream15

Septicemia: “the presence of microorganisms or their toxins in the blood”15. This term is outdated and imprecise, and should be abandoned

Sepsis: “life-threatening organ dysfunction caused by a dysregulated host response to infection” (SEPSIS-3)14

Septic shock: “a subset of sepsis in which underlying circulatory and cellular metabolism abnormalities are profound enough to substantially increase mortality” (SEPSIS-3)14,20

Maternal sepsis, defined by the World Health Organization: “a life-threatening condition defined as organ dysfunction resulting from infection during pregnancy, childbirth, post-abortion, or post-partum period.”17

An early attempt to codify definitions of sepsis came in 1991, when a consensus conference created four categories of severity, starting with systemic inflammatory response syndrome (SIRS) and proceeding to septic shock.15 A redefinition following a 2001 conference only served to complicate matters further by adding multiple possibilities for variables which could be used to identify sepsis16 (see Box 2). Many of these variables were predicated on sophisticated monitoring or laboratory assessment, which limited applicability. In the years following the second consensus conference, a great deal of variability in criteria complicated epidemiology and research, and an increased understanding of molecular mechanisms underpinning sepsis, coupled with a need to distinguish sepsis per se from simple infection, prompted further reconsideration by an expert panel in 2014 and 2015. The current SEPSIS-3 definitions are radically simpler (see Box 1), and categories have been collapsed from four into two: sepsis and septic shock only.

Box 2 Previous classification systems for sepsis and related conditions

1991 ACCP/SCCM Consensus Conference15

Systemic inflammatory response syndrome (SIRS): a host response to any of several clinical insults, not all of which are infection (i.e. pancreatitis, trauma, severe burns could also trigger SIRS). Any two of the following equaled a diagnosis of SIRS:

  • Temperature >38°C or <36°C
  • Heart rate >90/min
  • Respiratory rate >20/min, or PaCO2 <32 torr (<4.3 kPa)
  • White blood cell (WBC) count >12,000 cells/mm3, or <4000 cells/mm3, >10% immature forms (bands).

Sepsis: the manifestation of the systemic response specifically in response to infection; same criteria as SIRS

Severe sepsis: sepsis associated with organ dysfunction, hypoperfusion, or hypotension. Hypoperfusion included oliguria, lactic acidosis, or acute change in mental status

Septic shock: sepsis with hypotension (despite adequate fluid resuscitation) and markers of hypoperfusion. Hypotension is defined as systolic blood pressure (BP) <90 mmHg, or a reduction in systolic BP >40 mmHg from baseline

2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference16

Kept the four-tier classification system adopted in 1991, but expanded the list of criteria in an attempt to make them clinically comprehensive. Many possible signs of systemic inflammation were added to a table of diagnostic criteria for sepsis. Thus sepsis was understood to be infection, confirmed or suspected, plus some of the following:

General variables
  • Fever (>38.3°C)
  • Hypothermia (<36°C)
  • Heart rate >90/min, or >2 standard deviations above the normal value for age
  • Tachypnea (not specified)
  • Altered mental status
  • Significant edema (not specified) or positive fluid balance (>20 ml/kg over 24 h)
  • Hyperglycemia (plasma glucose >120 mg/dl or >7.7 mmol/L) in the absence of diabetes.
Inflammatory variables
  • Leukocytosis (WBC >12,000/μL)
  • Leukopenia (WBC <4000/μL)
  • WBC normal but >10% immature forms (bands)
  • Plasma C-reactive protein (CRP) >2 standard deviations above normal
  • Plasma procalcitonin >2 standard deviations above normal.
Hemodynamic variables
  • Hypotension (systolic BP <90 mmHg, mean arterial pressure (MAP) <70, or a decrease in systolic BP more than 40 mmHg in adults or a decrease more than 2 standard deviations below normal for age
  • SvO2 (mixed venous oxygen saturation) >70%
  • Cardiac index >3.5 L/min/M2 .
Organ dysfunction variables
  • Arterial hypoxemia (PaO2/FIO2 <300, where PaO2 is the partial pressure of oxygen in blood and FIO2 is the fraction of inspired oxygen)
  • Acute oliguria (urine output <0.5 ml/kg/h for at least 2 h)
  • Increase in serum creatinine more than 0.5 mg/dl
  • Coagulation abnormalities (international normalized ratio [INR] >1.5 or activated partial thromboplastin time (aPTT) >60 s
  • Ileus (absent bowel sounds)
  • Throbocytopenia (platelet count <100,000/μL)
  • Hyperbilirubinemia (plasma total bilirubin >4 mg/dl or 70 mmol/L).
Tissue perfusion variables
  • Hyperlactatemia (>1 mmol/L)
  • Decreased capillary refill or mottling.

Sepsis has recently been redefined as “life-threatening organ dysfunction caused by a dysregulated host response to infection”.14 The focus has shifted from signs of infection per se to signs of organ dysfunction or failure. Following release of the SEPSIS-3 guidelines, an expert panel at the World Health Organization arrived at a consensus definition of maternal sepsis in line with current understanding: “Maternal sepsis is a life-threatening condition defined as organ dysfunction resulting from infection during pregnancy, childbirth, post-abortion, or post-partum period”.17

A full assessment for organ dysfunction is based on the SOFA (sequential organ failure assessment) score: an increase of ≥2 points above baseline identifies organ dysfunction. In a patient not already known to have organ dysfunction, the baseline SOFA score is assumed to be zero (Table 1). However, clinicians outside the ICU may not be familiar with the SOFA score, and since four of the variables require laboratory testing, scoring may not be quick enough for early identification. In response, the Sepsis-3 group developed a quick SOFA (qSOFA) score which can be applied at the bedside.14 This model assigns 1 point for any of the following:

  • Systolic blood pressure ≤100 mmHg;
  • Respiratory rate ≥22/min;
  • Altered mental status.

A qSOFA score of 2 or 3 does a good job of identifying patients with suspected infection who are at risk of poor outcome, inasmuch as some organ compromise is already present. The predictive value is less than that of the full SOFA score, but the qSOFA score is immediately available at bedside, requires no laboratory assessment, and is easy to repeat. The panel recommended that an elevated qSOFA score should prompt clinicians to further investigate for organ dysfunction, to begin or ramp up therapy, to increase the frequency of monitoring (or consider critical care referral), and in patients not already believed to be infected, to consider the possibility of infection/sepsis as a cause. It is important to note that fever is not necessary or sufficient to the diagnosis of sepsis.

Conventional critical care scoring systems have not had a good track record when applied to obstetric populations. For example, APACHE-II overestimates mortality in these patients by a factor of 4,18 which reflects the absence of pregnant women from the sample set originally used to develop the prognostic model; the normal physiology of pregnancy is not accounted for. Before uncritically adopting the SOFA and qSOFA scores as screens for sepsis in pregnancy, it would be ideal to validate them in obstetric patients (a task obviously made more difficult by the absence of a diagnostic test for sepsis). It probably makes sense to adjust both the SOFA and qSOFA scores for the physiologic alterations of normal pregnancy. Though mental status and respiratory rate are not affected by pregnancy, other parameters often are. A working group from the Society of Obstetric Medicine of Australia and New Zealand (SOMANZ) has proposed obstetrically modified scores which they call the omSOFA and omqSOFA.19 The obstetrically modified qSOFA score (omqSOFA) also evaluates three parameters at the bedside and considers a score of 2 or 3 to be abnormal:

  • Systolic BP <90 mmHg;
  • Respiratory rate ≥25/min (this cutoff was based on regional bedside maternity observation charts);
  • Not alert.

With a screening omqSOFA score of 2 or 3, the group recommends that sepsis be considered and further testing for infection and organ dysfunction be undertaken. They also recommend that an omSOFA score ≥2 be understood as organ dysfunction and sepsis should therefore be considered. At the time of this writing (summer 2018) no research has yet been published using either the omqSOFA or omSOFA score, though they seem a promising start.

Septic shock, the second category in the Sepsis-3 guidelines, is defined as “a subset of sepsis in which underlying circulatory and cellular metabolism abnormalities are profound enough to substantially increase mortality.”14,20 Operationally, this means hypotension (MAP ≤65 mmHg) requiring vasopressors, plus a serum lactate level above 2 mmol/L, despite adequate volume resuscitation. In patients meeting all of these criteria, Sepsis-3 found mortality rates ranging from 35% to 54%.14,20 Mortality rose in proportion to serum lactate, though higher lactate levels do not necessarily equate to worse tissue perfusion: lactate is a marker of cellular and metabolic stress. Serum lactate levels do not change in pregnancy, and hyperlactatemia does predict higher morbidity among pregnant women presumed to have sepsis.21 Identifying the threshold for pathologic hypotension in a pregnant woman is, however, more difficult. In a longitudinal study of blood pressure in 57 normal women during pregnancy, Grindheim et al. determined that the MAP averaged 76–81 mmHg, depending on gestational age, and systolic BP averaged 104–109 mmHg.22 Extending the normal range to 2 standard deviations below the mean, 65 mmHg would thus be a reasonable lower boundary for MAP in normal pregnancy, and 88–92 mmHg for systolic BP. At this time, no one has validated a blood pressure cutoff for septic shock in pregnancy, but the SOMANZ group19 recommends no change to the MAP cutoff of 65 mmHg that applies outside of pregnancy. Blood pressure in pregnancy is, of course, subject to variation based on maternal position, so it is important to confirm that hypotension is not due purely to vena cava compression when a woman is lying supine. At later gestational ages there may also be a role for the electronic fetal heart rate tracing in the diagnosis of hypoperfusion: this may help the clinician decide whether a given maternal BP is adequate or too low.


Is pregnancy protective or predispositive to sepsis? This is a difficult question to answer, since both the incidence and the mortality of sepsis depend on age, making it difficult to find an appropriate comparison group of women of reproductive age. Analysis of the US National Inpatient Sample for “severe sepsis” hospitalizations in 2007 calculated the incidence as 35/100,000 among adults 18–24, 44 per 100,000 for age 25–29, 66 per 100,000 for age 30–34, 78/100,000 for age 35–39, 118/100,000 for age 40–44, and >800/100,000 for those aged >65.23, In each age group, the incidence at least doubled between 2000 and 2007, though mortality declined: the overall case–fatality rate of 39.6% in 2000 dropped to 27.3% in 2007. The authors were unable to extract the specific rate for reproductive-age women from this paper. A study of 101,064 patients with “severe sepsis” between 2000 and 2012, drawn from a database of adult ICU patients in Australia and New Zealand, calculated mortality in the subgroup of adults aged ≤44 years (n = 15,471) as 22.1% in 2000, declining to 7.3% in 2012, an impressive 67% drop.24 Survival does not, however, equal intact survival. In the US study, only about 28% of survivors of sepsis were discharged home, while twice as many were discharged to a skilled nursing facility;23 most of the patients in this study were much older than the reproductive-age group to which this chapter relates. In the Australia/NZ study, 12% of the young adult survivors (≤44) were not discharged home; they were transferred to another hospital or to a rehabilitation facility.24

Epidemiology of sepsis in pregnancy and puerperium

Early work on sepsis in pregnancy relied on case series. Population-based studies are now, fortunately, available. As in sepsis epidemiology generally, there are still questions of case ascertainment and sepsis definition, but uniquely in maternal sepsis, one must make a decision about what to use for the denominator: researchers have used live births, delivery hospitalizations, and estimated total pregnancies. Numbers from large case–control or cohort studies do not line up entirely with coding-based administrative datasets.

In The Netherlands, a national cohort study found the incidence of sepsis in pregnancy and the puerperium to be 2.1 per 10,000 deliveries, between 2004 and 2006,25 with a case–fatality rate of 7.7%. The United Kingdom Obstetric Surveillance System (UKOSS), in a large case–control study, estimated 4.7 per 10,000 maternities were complicated by severe sepsis, including septic shock, between 2011 and 2012.26 Less than one-third of these, however, were admitted to intensive care (ICU), which may reflect either a low degree of severity or a high threshold for ICU admission. Data for the US are derived from large administrative databases, either at the state or national level.27,28,29 Figures for maternal sepsis drawn from the National Inpatient Sample (NIS) range from 2 to 4 per 10,000 delivery hospitalizations in the early 2000s.28,29

By linking California vital statistics to hospital discharge data for all in-hospital live births between 2005 and 2007, Acosta et al. calculated a rate of “uncomplicated sepsis”, including “septicemia”, of 5.0 per 10,000, plus another 4.5 per 10,000 who had “severe sepsis”, including septic shock, for a total of nearly 10 cases of maternal sepsis per 10,000 live births.30 There seems to be a real trend toward increasing sepsis rates in the obstetric population. The NIS data showed a doubling in rates between 2003 and 2008.28 A detailed analysis of pregnancy-associated severe sepsis at delivery hospitalization in Texas also demonstrated a doubling in pregnancy-associated severe sepsis, from 6 per 10,000 in 2001 to 12 per 10,000 in 2010, using total estimated pregnancies as the denominator.31

In the Texas study, delivery hospitalizations accounted for only about one-third of pregnancy-associated severe sepsis hospitalizations: when abortions and fetal losses were included, the incidence of pregnancy-associated severe sepsis rose from 11 per 10,000 estimated pregnancies in 2001 to 26 per 10,000 in 2010. The authors pointed out that studying severe sepsis only at the time of delivery hospitalization severely underestimates the burden of disease in an obstetric population.31 Mortality in this Texas cohort was 9.7% in 2001 and 12% in 2010; of survivors, only 72–78% were simply discharged to home. The remainder required transfer to a long-term care facility, a short-term care facility, or additional care at home. How this plays out for the new mother, the new baby, or the family, is not detailed.

Case series and cohort studies have described patterns among antepartum and postpartum sepsis. Over a 30-year period, 66 women with maternal sepsis were admitted to ICU in a single hospital in a suburb of Paris, two-thirds of whom were antepartum, the majority from a “nonpelvic” source, mostly lung or urinary tract.30 More recently, in two Dublin hospitals between 2005 and 2012, 276 cases of bacteremia were identified among pregnant and postpartum women: 17% were antepartum, 47% were postpartum, and 36% were described as “intrapartum”.32 Among the antepartum cases, 41% were attributed to genital and 46% to urinary sources. Ninety percent of intrapartum cases arose from a genital source; among the postpartum cases, 54% were genital and 25% urinary. It must be pointed out, however, that bacteremia does not equal sepsis, as a significant proportion of clinical sepsis has no positive blood culture, and bacteremia alone is not commonly associated with organ failure; in the Dublin study, only 2.6% of women actually required ICU admission. At the other end of the spectrum of severity, in a series of maternal deaths due to sepsis, 39% of cases were antepartum in onset, though these included first-trimester losses and abortion.33

Unfortunately, population-based studies do not always separate antepartum from postpartum cases. The few we do have come from several high-income countries. In The Netherlands, 43% of severe maternal sepsis was antepartum, with a case–fatality rate of 11%, compared to the case–fatality rate of 3% for postpartum sepsis.25 These researchers classified causes as obstetric (56%) and nonobstetric (44%): of the nonobstetric causes, urinary tract infection accounted for about 32% and pneumonia for nearly 18%; almost 15% to appendicitis. In the UK, 37% of severe sepsis occurred antepartum, and the risk of death was 1.5%, no different from the postpartum risk of 1.3%.26 Antepartum sepsis was attributed to the urinary tract in 34%, to the genital tract in 20%, and to pneumonia in 9%. In 30%, no source was identified. Postpartum, 37% were from the genital tract, 12% from the urinary tract, 14% from wound infection, about 4% were respiratory in origin, and in 24%, no source was identified.

An audit of 646 pregnant and “recently pregnant” women admitted to intensive care units (ICU) in England, Wales, and Northern Ireland with a diagnosis of severe sepsis or septic shock (using the 2001 criteria) identified respiratory infection as the most common cause overall (approximately 40%); these women also had a longer length of stay in ICU and a higher absolute risk of death, compared with other causes of sepsis.34 Among pregnant women, who accounted for approximately 34% of the sample, leading causes of sepsis resulting in ICU admission were pneumonia, pyelonephritis, and appendicitis, while among the “recently pregnant” (within 6 weeks), the predominant causes were genital tract infection, wound infection, or “septicemia”. Both incidence and mortality of sepsis rose linearly with social deprivation. Overall, the maternal mortality rate was 4.6% and the stillbirth rate 7.2%.34

In the near future, we expect to have a great deal more information about the epidemiology of maternal sepsis. The World Health Organization launched a huge cross-sectional study of maternal (and newborn) sepsis across Latin America, Africa, Europe, Oceania, and Asia, during a single week in November 2017.35 During that week, facilities in participating geographical areas collected information on all women admitted to hospitals and healthcare facilities with suspected or confirmed infection at any stage of pregnancy – antepartum, in all trimesters; intrapartum; and postpartum and postabortal (including miscarriage) up to 42 days after pregnancy ended. Nearly 3000 women are likely to have been included in this observational study, the results of which are expected to be published in 2019. The study investigators hope to be able to validate identification criteria for maternal sepsis as well as address quality improvement strategies for management.

Risk factors for sepsis and for sepsis-related mortality

In the general adult population (not specifically in pregnancy), major risk factors associated with sepsis are age and medical comorbidity.23,36 Since pregnant and postpartum women are young, studies of younger adults are preferable to studies of the general adult population as a comparison; in a large observational study of sepsis and septic shock from Australia and New Zealand, which included 15,471 adults under age 44, young adults without comorbidities (as defined by the APACHE-II or APACHE-III chronic health classification system) had an 8% risk of in-hospital mortality, compared to a 24% risk for those with comorbidity.24

Most epidemiologic data on sepsis, including mortality, comes from high-income countries, though these make up only about 13% of the world population.37 At the national and cross-national level, there does appear to be both a higher incidence of sepsis and a higher case–fatality rate in low- and middle-income countries (LMIC), compared with high-income countries.38,39 Cross-national comparisons focused specifically on maternal sepsis are even harder to come by, though the GLOSS study35 is likely to remedy that. In one survey focused on maternal deaths across 40 LMIC, using a national data collection tool called emergency obstetric and newborn care (EmONC) assessments, case–fatality rates for postpartum sepsis were reported to range from a low of ≤1% (Afghanistan, Bangladesh, Cambodia, Burundi, Djibouti, Gambia, Liberia, Namibia, Niger, Ecuador, Guyana, Haiti, Nicaragua, and Panama), to ~5–10% (Angola, Chad, Benin, Eritrea, Ethiopia, Ghana, Guinea, Malawi, Mauritania, Mozambique, Niger, Senegal, Togo), to 15% or higher in Mongolia, Zambia, Congo, and Lesotho.40 Data collection is, of course, more limited in those LMIC where the rate of healthcare facility-based deliveries is low.

In high-income countries with near-universal hospital-based deliveries and robust statistical data collection, demographic and medical factors have been studied as contributors to the risk of sepsis in obstetrics. Though many risk factors have been put forward, the literature is not consistent. Drawing from large population-based studies, there seems to be a modest increase in risk (adjusted odds ratio less than 2.0) for nulliparas, African ancestry, age ≥35, and lower socioeconomic status, as represented by low levels of education, residence in a high-poverty neighborhood, and public or no insurance.25,26,27,30,31 Obesity was a slight risk factor in one study,31 with an odds ratio of 1.4, but not in others.25,26,27

Specific obstetric factors associated with higher risks for sepsis include:

  • Assisted reproductive technology (odds ratio [OR] 5.8);25
  • Multiple pregnancy (OR 1.8–6.5) in some studies,25,27 though not in others;30
  • Cervical cerclage (OR 3.4–9.8);27
  • Preterm premature rupture of membranes (PPROM) and preterm delivery (OR 2.1–3.0) in some studies,27,28 but not others;25,26
  • Cesarean delivery, both prelabor and in-labor (OR 1.8–8.1);25,26,28,29
  • Retained placenta or products of conception (OR 4.5) in one27 study, but not in another;26
  • Peripartum hysterectomy (OR 56) and blood transfusion (OR 10.9) were associated with significantly increased risk for sepsis;28
  • Gestational diabetes was protective where separately analysed (OR 0.54);31
  • Pregestational diabetes was associated with a range of risks, from no increased risk27 to moderate risk (OR 1.8–4).28,31

Medical comorbidity played a significant role in sepsis risk, in studies where it was explicitly assessed. Chronic renal disease (adjusted odds ratio [aOR] 33), chronic liver disease (aOR 55), and especially congestive heart failure (aOR 135)27 outweighed all other risk factors, including HIV infection (aOR 3.2–4.2).27,31

Microbiologic assessment

Information is limited on the pathogens responsible for maternal sepsis, since in many reports, microbiology is not specifically addressed. In the United Kingdom Obstetric Surveillance System,26 which is among the largest and most meticulous reports, the clinical laboratory was only able to identify the microorganism in 64% of maternal sepsis cases, and the clinician could identify the source in only 74%. Remarkably, in 16%, neither the inciting organism nor the source of sepsis was known. These figures are consistent with the overall experience of sepsis in a general adult population, in which blood cultures are negative in two-thirds of patients with sepsis, and cultures from all sites are negative in one-third.41 The most frequently isolated organisms in maternal sepsis are Escherichia coli, group A and group B streptococcus,25,26 though staphylococci, Gram-negatives, anaerobes, and many other organisms have been reported.32,42 Mixed infections are also possible; in 15% of maternal sepsis deaths in which organisms could be identified, infection was polymicrobial.33

New techniques including molecular techniques are emerging as a supplement to culture-based identification for bloodstream infections. Peptide nucleic acid fluorescent in situ hybridization (PNA-FISH) stains, matrix-assisted laser desorption-ionization/time-of-flight (MALDI-TOF) mass spectroscopy, and polymerase chain reaction (PCR) based systems are commercially available and can provide pathogen identification from blood cultures in under 3 hours from the time cultures are positive.43 Additionally, it is possible to apply molecular techniques directly to whole blood samples, using PCR for the most common Gram-positive and Gram-negative bacteria plus several pathogenic fungi, which could shorten turnaround time still further.43 Concordance between whole-blood PCR and blood culture based techniques is nowhere near 100% at this time, however; detection failures by PCR probably relate to the choice of organisms included in the panel. Interestingly, about 11% of patients with a clinical suspicion of bacteremia but negative blood cultures are reported to have a positive PCR.44 Adding molecular and other new techniques to culture-based testing would likely reduce the number of cases in which no organism is identified in suspected sepsis.

Altered pregnancy physiology and the recognition of sepsis

Normal human pregnancy is a state of expanded plasma volume, increased cardiac output, and peripheral vasodilation; these are also features of sepsis. In an earlier era, when the Swan-Ganz catheter was routinely employed in severe sepsis, the hemodynamic picture of sepsis was so similar to that of normal pregnancy that obstetricians had to caution intensivists about jumping to conclusions.

None of the extant definitions of sepsis were modeled on pregnant patients, and they do not account for the alterations in normal physiology which are characteristic of pregnancy. When nonpregnant norms are used, either overdiagnosis or underdiagnosis of sepsis may occur. An analysis of normal maternal physiologic parameters45 compared to the 1992 sepsis criteria15 showed that SIRS and sepsis cutoffs for respiratory rate, heart rate, PaCO2 and white blood cell count overlapped with the normal range for pregnancy, labor, and/or the early puerperium, which vitiates their value in diagnosing sepsis in obstetrics. The high false-positive rate is one problem, but additionally, the obstetrician may under-react to sepsis signals, being accustomed to a degree of tachycardia or leukocytosis in normal pregnancy.

Recognition of sepsis

A high index of suspicion is needed to recognize sepsis in pregnancy and the puerperium. Because there is no diagnostic test, expedited clinical recognition is key. Infection may be recognized and sepsis nevertheless missed; or the patient may be identified as having organ dysfunction but an underlying infection may go undiagnosed. To reiterate the WHO definition: “Maternal sepsis is a life-threatening condition defined as organ dysfunction resulting from infection during pregnancy, childbirth, post-abortion, or post-partum period”.17 The full SOFA score is shown in Table 1, the qSOFA score in Table 2, the obstetrically modified SOFA score in Table 3 and the obstetrically modified qSOFA score in Table 4. Using either the qSOFA score from the Sepsis-3 investigators,14 or the omqSOFA score proposed by the SOMANZ group19 (Tables 2 and 4), pregnant and postpartum patients should be screened at the bedside for sepsis. Though fever is often related to infection, it is neither sensitive nor specific in sepsis. Early warning systems have been adapted for use in maternal care and can provide a formal review of maternal status, repeated at regular intervals.46,47,48


Sequential organ failure assessment (SOFA) score.14

System parameter






Respiratory: PaO2/FIO2

>400 mmHg
(53.3 kPa)

<400 mmHg
(53.3 kPa)

<300 mmHg
(40 kPa)

<200 mmHg
(26.7 kPa) with respiratory support

<100 mmHg
(13.3 kPa) with respiratory support

Coagulation: platelets (×103/μL)






Hepatic: bilirubin

<1.2 mg/dL (20 μmol/L)

1.2–1.9 mg/dL
(20–32 μmol/L)

2.0–5.9 mg/dL
(33–101 μmol/L)

6.0–11.9 mg/dL
(102–204 μmol/L)

>12 mg/dL
(204 μmol/L)

Cardiovascular: MAP (mean arterial pressure)

≥70 mmHg

<70 mmHg

Dopamine <5 μg/kg/min, or any dose dobutamine

Dopamine 5.1–15 μg/kg/min, or epinephrine ≤0.1 μg/kg/min, or norepinephrine ≤0.1 μg/kg/min

Dopamine >15 μg/kg/min, or epinephrine >0.1 μg/kg/min, or norephinephrine >0.1 μg/kg/min

Central nervous system: Glasgow Coma Scale score






Renal: Serum creatinine

<1.2 mg/dL (110 μmol/L)

1.2–1.9 mg/dL (110–170 μmol/L)

2.0–3.4 mg/dL
(171–299 μmol/L)

3.5–4.9 mg/dL
(300–440 μmol/L)


Urine output <500 mL/day

>5.0 mg/dL
(440 μmol/L)


Urine output <200 mL/day


Quick sequential organ failure assessment (SOFA) score (qSOFA).14

Assign 1 point for each of the following. A score >1 is abnormal, and further investigation is indicated

  • Systolic blood pressure ≤100 mmHg
  • Respiratory rate ≥22/min
  • Altered mental status


Obstetrically modified sequential organ failure assessment (SOFA) score (omSOFA).19


System parameter




Respiration: PaO2/FIO2




Coagulation: platelets (×103/μL)




Liver: bilirubin (μmol/L)




Cardiovascular: MAP (mmHg)



Vasopressors required



Rousable to voice

Rousable to pain

Renal: creatinine (μmol/L)





Obstetrically modified quick sequential organ failure assessment (SOFA) score (omqSOFA).19

Assign 1 point for any of the following. A score >1 should prompt the clinician to consider sepsis and conduct further evaluation

  • Systolic BP <90 mmHg
  • Respiratory rate ≥25/min
  • Mental status other than alert

If a patient screens positive for sepsis with a rapid bedside assessment, further evaluation is indicated, specifically, a careful search for infection and organ dysfunction. History, physical examination, and laboratory testing should be deployed in a focused way. Cultures should be obtained from blood and from any suspected source, but the process should not be allowed to delay initiation of antimicrobials, as delay in therapy increases mortality.


Antibiotics should be initiated as soon as possible, ideally within the first hour after sepsis is suspected or diagnosed. The Surviving Sepsis Campaign (SSC) (, a project of several international organizations, has released several iterations of guidelines since 2004. Earlier guidelines had both a 3-hour and a 6-hour bundle of practices to implement, but the most recent set, released in 2018, is explicit in recommending a 1-hour bundle.49 Recognition, resuscitation, and treatment should be initiated immediately. The components of this bundle are shown in Box 3.

Box 3 Hour-1 care bundle, from Surviving Sepsis Campaign, 2018 update49

  • Measure lactate level. Remeasure if initial lactate >2 mmol/L
  • Obtain blood cultures prior to administration of antibiotics
  • Administer broad-spectrum antibiotics
  • Begin rapid administration of crystalloid (30 mL/kg) for either hypotension or lactate ≥4 mmol/L
  • Start vasopressors if the patient is hypotensive during or after fluid resuscitation, to maintain MAP ≥65 mmHg.

Delay in starting antimicrobials increases mortality from sepsis.50 Although the relationship between delay and death has not been tested specifically in an obstetric population, there is no reason to suspect it would be different. In a review of 50 pregnant or postpartum women admitted to ICUs in New Zealand with a diagnosis of “severe sepsis”, 50% of cases were judged to have been preventable, most of them owing to delay in treatment; delay in recognition or diagnosis also was a factor.51 Mortality from sepsis rises linearly with each hour of delay. Once cultures have been obtained and antibiotics started, the clinician should begin a search for a locus of infection which may be amenable to source control: for example, an infected wound should be opened, retained products of conception should be evacuated, etc.

The choice of antibiotic depends on presumed source, likely microorganism, local patterns of antibiotic resistance, and the hospital’s stock of agents, but should always be broad spectrum to start. The Infectious Disease Society of America convened a working group in 2016 to make recommendations (not specific to pregnancy) as to appropriate initial empirical treatment of bacterial sepsis;52 the group offered options for both monotherapy and combination therapy (see Boxes 4 and 5). Suggestions for monotherapy included third- to fifth-generation cephalosporins, piperacillin-tazobactam, or carbapenems. The working group recommended, as combination therapy, that either an aminoglycoside or aztreonam be given for Gram-negative coverage, and an additional agent (e.g., a penicillin, glycopeptide, linezolid, daptomycin) to cover Gram-positive and anaerobic bacteria (see Box 5).

Box 4 Sepsis National Hospital Inpatient Quality Measure (SEP-1) multistakeholder work group recommendations for the treatment of sepsis52 empiric antibiotic therapy for sepsis (monotherapy)

Choose one:

  • Cephalosporins
    • Cefipime
    • Cefotaxime
    • Ceftaroline fosamil
    • Ceftazidime
    • Ceftriaxone
  • Carbepenems
    • Ertapenem
    • Imipenem/cilastatin
    • Meropenem
  • Ureidopenicillin plus beta-lactamase inhibitor
    • Piperacillin-tazobactam

Box 5 Sepsis National Hospital Inpatient Quality Measure (SEP-1) multistakeholder work group recommendations for the treatment of sepsis52 empiric antibiotic therapy for sepsis (combination therapy)

Choose 1 from column A, plus 1 from corresponding column B

Column A

Column B



Cephalosporins, or

daptomycin, or

linezolid, or

penicillins, or











Daptomycin, or

linezolid, or

penicillins, or

clindamycin (intravenous), or


tides (see above)

Other specialty organizations have made antibiotic recommendations specific to antepartum or postpartum sepsis, or at least to specific types of maternal infection. The Royal College of Obstetricians and Gynaecologists (RCOG) recommends piperacillin/tazobactam, or a carbapenem plus clindamycin, as broad coverage in postpartum sepsis53 (Box 6). The Society of Obstetric Medicine Australia and New Zealand (SOMANZ) offers recommendations for treatment of maternal sepsis with unknown source, divided into those cases that are community-acquired and those that are hospital-acquired;19 the recommendations in New Zealand are the same either way, while in Australia they are different (Box 7).

Box 6 Royal College of Obstetricians and Gynaecologists (RCOG) guidelines for treatment of postpartum sepsis53

Piperacillin/tazobactam, or

Clindamycin plus a carbapenem

If MRSA is likely or suspected, add a glycopeptides (vancomycin, teicoplanin) until sensitivity to clindamycin is known.

Box 7 Society of Obstetric Medicine Australia and New Zealand (SOMANZ) guidelines for treatment of maternal sepsis with unknown source19

Community-acquired sepsis, source not apparent:

Australia: amoxicillin/ampicillin 2 g IV q6 h plus gentamicin 4–7 mg/kg first dose* plus metronidazole 500 mg IV q12 h

New Zealand: cefuroxime 1.5 g IV q8 h, plus gentamicin 4–7 mg/kg first dose* plus metronidazole 500 mg IV q12 h

(alternative if penicillin-allergic: cefazolin plus gentamicin, or clindamycin plus gentamicin).

Hospital-acquired sepsis, source not apparent:

Australia: piperacillin 4 g + tazobactam 0.5 g IV q8 h, and consider gentamicin 4–7 mg/kg first dose*, depending on local Gram-negative resistance patterns

New Zealand: cefuroxime 1.5 g IV q8 h, plus gentamicin 4–7 mg/kg first dose*, plus metronidazole 500 mg IV q12 h

(alternative if penicillin-allergic: ciprofloxacin 400 mg IV q8 h plus vancomycin 25–30 mg initial dose, then local protocol for dosing).

If methicillin-resistant Staphylococcus aureus (MRSA) is suspected (previous culture or local epidemiology): add vancomycin 25–30 mg/kg loading dose, then follow local protocol for dosing.

If Group A streptococcal sepsis is suspected: add clindamycin 600 mg IV q8 h.

If multidrug-resistant Gram-negative organisms are suspected in hospital-acquired sepsis with unknown source: meropenem 1 g IV q8 h as a single agent.

*Note: after the initial dose of gentamicin SOMANZ advise following local protocols for dosing, whether once-daily or q8 h.

The World Health Organization (WHO) rather tepidly suggests ampicillin plus once-daily gentamicin for suspected chorioamnionitis, and clindamycin plus gentamicin for postpartum endometritis, though they do not offer recommendations for maternal sepsis per se (Box 8).54 Nor has the American College of Obstetricians and Gynecologists published specific recommendations for antibiotic treatment of maternal sepsis, though they have weighed in on intra-amniotic infection generally55 (Box 9).

Box 8 World Health Organization recommendations for treatment of maternal peripartum infection54

N.B. This document does not specifically address maternal sepsis, just infection.

For chorioamnionitis: “a simple regimen such as ampicillin and once-daily gentamicin is recommended as first-line antibiotics … Conditional recommendation based on very low-quality evidence. There is insufficient evidence to support the use of any antibiotic over any other. Based on consensus, the Guidelines Development Group favoured a recommendation that is simple, can be administered over a short duration, and follows the principles of antibiotic use to reduce emergence of resistant strains of bacteria.”

For postpartum endometritis: “a combination of clindamycin and gentamicin is recommended for the treatment of postpartum endometritis. Conditional recommendation based on very low-quality evidence. The Guidelines Development Group acknowledged that availability and costs of clindamycin might be limiting factors in low-resource-settings, and suggested the use of a penicillin class of drug as alternative treatment in such contexts.”

Box 9 American College of Obstetricians and Gynecologists (ACOG) recommendations for treatment of intra-amniotic infection55

N.B. This document does not specifically address maternal sepsis, just infection.

Primary recommendation: ampicillin 2 g IV q8 h plus gentamicin (either 2 mg/kg IV loading dose followed by 1.5 mg/kg q8 h, or 5 mg/kg q24 h)

In case of penicillin allergy: cefazolin 2 g IV q8 h plus gentamicin (dose above).

In case of severe penicillin allergy: clindamycin (900 mg IV q8 h) or vancomycin (1 g IV q12 h), plus gentamicin (dose above.)

Alternative recommendations: ampicillin-sulbactam; piperacillin/tazobactam; ertapenem. (ACOG also suggests cefotetan and cefoxitin as alternative treatments for intra-amniotic infection, but these drugs are inadequate as monotherapy for sepsis: see reference 55)

Antibiotic coverage should be narrowed and focused once culture results are available, which in most cases will take several days. The duration of treatment will depend on patient response and on the particular source or pathogen involved.

Source control is an important tool for addressing infection.56 If the host inflammatory response is successful in isolating a bolus of microorganisms, along with debris from tissue fluid, coagulation elements, and host inflammatory cells, within a fibrin capsule, the abscess thus formed locks pathogens away from systemic dissemination, but also limits the ability of host defenses to attack those pathogens. Local tissue may become necrotic. Uncontrolled abscess rupture carries a great risk of morbidity.

A diligent search for a focus of infection amenable to control should be carried out when sepsis is suspected. Physical examination should be supplemented, where needed, with appropriate diagnostic imaging. Source control is generally predicated on abscess drainage or debridement of necrotic, infected tissue, but in cases of obstetric sepsis with a uterine source, it will specifically be necessary to empty the uterus: delivery of the fetus and placenta is indicated. Postpartum (and post-abortal), it is important to ensure that no placental tissue or infected clot has been retained. With maternal sepsis from a nonuterine source, it is generally preferable to undertake source control via the intervention with the least likelihood of physiologic derangement; thus percutaneous abscess drainage, for example, is preferable to laparotomy. In under-resourced settings, general anesthesia and an open surgical procedure may not even be feasible in a timely fashion.

Fluid management in sepsis

Fluid resuscitation is the first intervention if hypotension or hypoperfusion is present. Fever, venodilation, and capillary leakage all tend to leave the septic patient inadequately preloaded. The Surviving Sepsis Campaign (SSC) recommends an initial bolus of 30 ml/kg of a balanced isotonic salt solution,49 but this recommendation may be overly aggressive in pregnancy, where colloid oncotic pressure is lower and the risk of pulmonary edema is higher. Only about 50% of hypotensive septic patients are fluid responders in any case, and in those who are not, aggressive fluid loading may produce diastolic dysfunction, pulmonary edema, and higher mortality.57 Point-of-care ultrasound has been used to identify fluid responsiveness either by measuring the diameter of the inferior vena cava (IVC diameter less than 1.5 cm predicts fluid responsiveness, while IVC diameter >2.5 cm suggests the patient is already fully fluid-loaded) or by measuring extravascular lung water.58 These tools have not been extensively evaluated in pregnancy, though obstetricians are well aware of the potential for IVC compression by a gravid uterus when a pregnant patient is supine, and reflexively will effect left uterine displacement when she is hypotensive in this position.

A quick and reversible test of fluid responsiveness can be performed with passive leg raising to 45 degrees: within a few minutes after passive leg raising, fluid responders can be identified by hemodynamic improvement, while those who do not improve are probably better treated with vasopressors.59 Limited data are available on this maneuver during pregnancy, however, and it may be technically difficult to execute or may not result in an augmentation of cardiac output in late pregnancy.60

Early goal-directed therapy (EGDT) in sepsis generated some enthusiasm in the early years of the 21st century. This required a central venous catheter be inserted and aggressive fluid resuscitation to a target central venous pressure 8–12 mmHg, accompanied by aggressive transfusion to hematocrit of ≥30%, and dobutamine as needed to reach a goal measure of mixed venous oxygen saturation.61 It was never tested in pregnant patients, and has since been demonstrated to worsen outcomes in adult sepsis generally.64,62,63 EGDT has no place in contemporary management of sepsis in obstetric patients.

The purpose of vasopressors is to constrict the pathologically dilated systemic circulation commonly seem in sepsis, and thereby maintain adequate perfusion. SSC recommends norepinephrine as the first-line agent and does not specify a hard target for mean arterial pressure (MAP), instead suggesting it be individualized.49 Intensivists often aim for a MAP of ≥65 mmHg, but this may be too high for a previously healthy young patient, and is probably too high in pregnancy. Values obtained from Grindheim22 in healthy pregnant subjects show 2 standard deviations below the mean to be about 65 mmHg, and 3 SD to be about 60 mmHg. As it happens, many pregnant patients have another easily accessible measure of perfusion available, as the fetal heart rate tracing is exquisitely sensitive to uteroplacental perfusion. Determining the target MAP in a septic pregnant patient must be individualized, with reference to overall organ perfusion, including (though not limited to) the fetal heart rate tracing.

Norepinephrine has been studied in human pregnancy and is used to maintain BP under regional anesthesia for cesarean.65 Acknowledging that data are limited in the setting of pregnancy-associated septic shock, norepinephrine nevertheless seems to be safe for fetuses, at least in low doses, in contrast to ongoing maternal shock, which is demonstrably unsafe. Additional reassurance as to its safety profile comes from a dual-perfused single-cotyledon model of human placenta, which showed that norepinephrine did not interfere with perfusion on the fetal side.66 The clinician should not hesitate to administer norepinephrine to a septic pregnant patient when it is otherwise indicated.


Preterm delivery is common after critical maternal illness, including sepsis, even when the source is not uterine. This is consistent with the pathophysiology of sepsis, in which inflammatory mediators are released systemically,4,6,7 and one might speculate that these mediators contribute to triggering labor. In an Irish series of pregnant and postpartum women with bacteremia – described as sepsis, but given low rates of organ failure and ICU admission, these women were less sick than we would currently understand as sepsis – the rate of preterm birth was 16.8%, nearly 3 times the rate in the control group at the institutions.32 This rate included women diagnosed with bacteremia antepartum, intrapartum, and postpartum. Examining only those women with antepartum bacteremia, 69% either miscarried or delivered preterm. The outcome was, as expected, even worse for women with antepartum bacteremia of uterine origin: all delivered within 24 hours of onset. Among women with a nongenital source of bacteremia in the antepartum period, it appears that 12% miscarried, 33% delivered soon after onset, and the remainder delivered between 1 week and 7 months after onset, but the exact details cannot be obtained from the paper. Bacteremia during pregnancy was associated with a 29% risk of preterm delivery in a French study, with an overall 10% rate of fetal mortality; when maternal bacteremia occurred during the second trimester, the fetal death rate was 40%.67 In a small but careful study focused specifically on E. coli bacteremia during pregnancy, the same researchers determined the rate of fetal death was 27% overall, despite adequate antibiotic therapy, and even when the microbiologic virulence score was low.68 In both these papers, maternal condition seems overall to have been good, with low rates of ICU admission and organ failure, and no deaths. One would anticipate that in women who are overtly septic, by current definitions involving organ failure, maternal and perinatal outcomes would be considerably worse.

Long-term outcomes

In the longer term, adults who have survived sepsis continue to have higher mortality rates than those who did not have sepsis.69 There are no data available on long-term maternal outcome after critical illness, including sepsis. Quality of life is impaired among sepsis survivors.69 Ongoing weakness, myopathy, and neuropathy are common among ICU survivors, as is psychological distress, e.g., depression and post-traumatic stress disorder (PTSD). More than 50% of sepsis survivors have a degree of long-term cognitive impairment,70 which should be borne in mind when planning hospital discharge. Almost nothing is known about recovery from critical illness during pregnancy, though a recent qualitative study points up weakness, frustration, isolation, anxiety, panic attacks, depression, and PTSD after the critical-illness hospitalization.71 Critical maternal illness also affects families and caregivers in ways which are only beginning to be evaluated. There is a great need for more research on these outcomes.


  • Sepsis is not simply infection. It is a syndrome of life-threatening organ dysfunction stemming from a dysregulated host response to infection.
  • There is no diagnostic test. Clinical suspicion is the foundation of recognition. A quick sequential organ failure assessment (qSOFA) score, or obstetrically modified version (omqSOFA score) is a quick assessment.
  • If unexplained organ dysfunction: consider sepsis and evaluate further. Fever is not necessary for diagnosis.
  • Cornerstone of treatment is administration of broad-spectrum antibiotics within the first hour after recognition. Delay increases mortality. Box 3 provides components of the 1-hour treatment bundle.
  • Fluid management is important in correcting hypoperfusion (low blood pressure, elevated serum lactate.)
  • Start with cultures and antibiotics; then look for a focus of infection amenable to source control.
  • Survival after sepsis is not the end of the story. Even when a pregnant or postpartum woman survives sepsis, she may be vulnerable to additional neuromuscular, cognitive, or mood dysfunction, and additional supports may be needed.


Author(s) statement awaited.



HSE Ireland. Final report: investigation of incident 50278 from time of patient’s self referral to hospital on the 21st of October 2012 to the patient’s death on the 28th of October, 2012. June 2013. Accessed 5/14/18


Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Global Health 2014;2:e323–33. PMID 25103301


Cohen J, Vincent JL, Adhikari NK, et al. Sepsis: a roadmap for future research. Lancet Infect Dis 2015;15:581–614. PMID 25932591


Wiersinga WJ, Leopold SL, Cranendonk DR, et al. Host innate immune responses to sepsis. Virulence 2014;5(1):36–4. PMID 23774844


van der Poll T, Opal SM. Host-pathogen interactions in sepsis. Lancet Infect Dis 2008;8:32–42. PMID 18063412


Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leucoc Biol 2007;81:1–5. PMID 17032697


Deutschman CS, Tracey KJ. Sepsis: current dogma and new perspectives. Immunity 2014;40:463–75. PMID 24745331


Boyd JH, Russell JA, Fjell CD. The meta-genome of sepsis: host genetics, pathogens and the acute immune response. J Innate Immun 2014;6:272–83. PMID 24525633


Opal SM, van der Poll T. Endothelial barrier dysfunction in septic shock. J Intern Med 2015;277:277–293. PMID 25418337


Mor G, Cardenas I. The immune system in pregnancy: a unique complexity. Am J Reprod Immunol 2010;63(6):425–33. PMID 20367629


Racicot K, Kwon J, Aldo P, et al. Understanding the complexity of the immune system during pregnancy. Am J Reprod Immunol 2014;72:107–16. PMID 24995526


Aagaard-Tillery KM, Silver R, Dalton J. Immunology of normal pregnancy. Semin Fetal Neonatal Med 2006;11:279–95. PMID 16784908


Aagaard K, Ma J, Antony KM, et al. The placenta harbors a unique microbiome. Sci Trans Med 2014;6;237ra65. PMID 24848255


Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock. JAMA 2016;315(8):801–10. PMID 26903338


American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20(6):1787–94. PMID 1597042


Levy MM, Fink MP, Marshall JC, et al., for the International Sepsis Definitions Conference. 2001 SCCM/ESICM/ACCP/ATS/SIS Internal Sepsis Definitions Conference. Crit Care Med 2003;31:1250–6. PMID 12682500.


Bonet M, Pileggi VN, Rijken M, et al. Towards a consensus definition of maternal sepsis: results of a systematic review and expert consultation. Reproductive Health 2017;14:67. doi 10.1186/212978–017–0321–6. PMID 29310684. PMCID PMC5757287


Ryan HM, Sharma S, Magee LA, et al. The usefulness of the APACHE II score in obstetric critical care: a structured review. J Obstet Gynaecol Can 2016;38:909–18. PMID 27720089


Bowyer L, Robinson HL, Barrett H, et al. SOMANZ guidelines for the investigation and management sepsis in pregnancy. Aust NZ Obstet Gynaecol 2017;57:540–51. PMID 28670748


Shankar-Hari M, Phillips GS, Levy MM, et al., for the Sepsis Definitions Task Force. Developing a new definition and assessing new clinical criteria for septic shock. For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016;315(8):775–87. PMID 26903336


Albright CM, Ali TN, Lopes V, et al. Lactic acid measurement to identify risk of morbidity from sepsis in pregnancy. Am J Perinatol 2015;32:481–6. PMID 28885400


Grindheim G, Estensen M-E, Langesaeter E, et al. Changes in blood pressure during healthy pregnancy: a longitudinal cohort study. J Hypertens 2012;30:342–50. PMID 22179091


Kumar G, Kumar N, Taneja A, et al., from the Milwaukee Initiative in Critical Care Outcomes Research (MICCOR) Group of Investigators. Nationwide trends of severe sepsis in the 21st century (2000–2007). Chest 2011;140:1223–31. supplemental material, e- table 6 PMID 21852297


Kaukonen KM, Bailey M, Suzuki S, et al. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012. JAMA 2014;311(13):1308–16. supplementary material, e-table 3 doi: 10.1001/jama.2014.2637. PMID 24638143


Kramer HMC, Schutte JM, Zwart JJ, et al. Maternal mortality and severe morbidity from sepsis in the Netherlands. Acta Obstet Gynecol Scand 2009;88:647–53. PMID 19412806


Acosta CD, Kurinczuk JJ, Lucas DN, et al., on behalf of the United Kingdom Obstetric Surveillance System. Severe maternal sepsis in the UK, 2011–2012: a national case-control study. PLoS Med 2014;11(7):e1001672. PMID 25003759


Bauer ME, Bateman BT, Bauer ST, et al. Maternal sepsis mortality and morbidity during hospitalization for delivery: temporal trends and independent associations for severe sepsis. Anesth Analgesia 2013;117:944–50. PMID 24023020


Al-Ostad G, Kezouh A, Spence AR, et al. Incidence and risk factors of sepsis mortality in labor, delivery, and after birth: population-based study in the USA. J Obstet Gynaecol Res 2015;41:1201–6. PMID 25976287


Callaghan WM, Creanga AA, Kuklina EV. Severe maternal morbidity among delivery and postpartum hospitalizations in the United States. Obstet Gynecol 2012;120:1029–36. PMID 23090519


Acosta CD, Knight M, Lee HC, et al. The continuum of maternal sepsis severity: incidence and risk factors in a population-based cohort study. PLoS ONE 8(7):e67175. doi:10.1371/journalpone.0067175. Published July 2, 2013. PMID 23843991


Oud L, Watkins P. Evolving trends in the epidemiology, resource utilization, and outcomes of pregnancy-associated severe sepsis: a population-based cohort study. J Clin Med Res 2015;7(6):400–16. PMID 25883702


Knowles SJ, O’Sullivan NP, Meenan AM, et al. Maternal sepsis incidence, aetiology and outcome for mother and fetus: a prospective study. BJOG 2015;122:663–71. PMID 25413773


Bauer ME, Lorenz RP, Bauer ST, et al. Maternal deaths due to sepsis in the state of Michigan, 1999–2006. Obstet Gynecol 2015;126:747–52. PMID 26348189


Acosta CD, Harrison DA, Rowan K, et al. Maternal morbidity and mortality from severe sepsis: a national cohort study. BMJ Open 2016;6:2.012323. doi:10.1136/bmjopen-2016–012323. PMID 27554107. PMCID: PMC5013336


Bonet M, Souza JP, Abalos E, et al. The global maternal sepsis study and awareness campaign (GLOSS): study protocol. Reprod Health 2018;15:16. DOI 10.1186/s12978–017–0437–8. PMID 29382352


Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303–1310. PMID 11445675


Fleischmann C, Scherag A, Adhikan NKJ, et al., on behalf of the International Forum of Acute Care Trialists. Assessment of global incidence and mortality of hospital-treated sepsis: current estimates and limitations. Am J Respir Crit Care Med 2016;193:259–72. PMID 26414292


Quintano Neira RA, Hamacher S, Japlassu AM. Epidemiology of sepsis in Brazil: incidence, lethality, costs, and other indicators for Brazilian Unified Health System hospitalizations from 2006 to 2015. PLoS ONE 2018;13(4):e0195873. PMID 29652944. PMCID: PMC5898754


Weng L, Zeng X, Yin P, Wang L, et al., for the China Critical Care Clinical Trials Group (CCCCTG). Sepsis-related mortality in China: a descriptive analysis. Intens Care Med 2018;44:1071–80. PMID 29846748


Bailey PE, Andualem W, Brun M, et al. Institutional maternal and perinatal deaths: a review of 40 low and middle income countries. BMC Pregnancy and Childbirth 2017;17:295. doi: 10.1186/212884–017–1479–1. PMID 28882128. PMCID: PMC5590194


Angus CD, van der Poll T. Severe sepsis and septic shock. New Engl J Med 2013;369:840–51. PMID 23984731


Drew RJ, Fonseca-Kelly A, Eogan M. A retrospective audit of clinically significant maternal bacteraemia in a specialist maternity hospital from 2001 to 2014. Infect Dis Obstet Gynecol 2015;2015:518562; doi.10.1155/2015/518562.Epub 2015 Oct PMID 26494975. PMCID: PMC4606170


Kothari A, Morgan M, Haake DA. Emerging technologies for rapid identification of bloodstream pathogens. Clin Infec Dis 2014;59(2):272–8. PMID 24771332


Warhurst G, Maddi S, Dunn G, et al. Diagnostic accuracy of SeptiFast multipathogen real-time PCR in the setting of suspected healthcare-associated bloodstream infection. Intens Care Med 2015;41:86–93. PMID 25406409


Bauer ME, Bauer ST, Rajala B, et al. Maternal physiologic parameters in relationship to systemic inflammatory response syndrome criteria: a systematic review and meta-analysis. Obstet Gynecol 2014;124:535–41. PMID 25162253


Maguire PJ, O’Higgins AC, Power KA, et al. Maternal bacteremia and the Irish maternity early warning system. Int J Gynecol Obstet 2015;129:142–5. PMID 25670063


Edwards SE, Grobman WA, Lappen JR, et al. Modified obstetric early warning scoring systems (MOEWS): validating the diagnostic performance for severe sepsis in women with chorioamnionitis. Am J Obstet Gynecol 2015;212:536.e1–8. PMID 25446705


Mhyre J, D’Oria R, Hameed AB, et al. The Maternal Early Warning Criteria: a proposal from the National Partnership for Maternal Safety. Obstet Gynecol 2014;124 782–6. PMID 25198266


Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. Crit Care Med 2018;46(6):997–1000. PMID 29767636


Ferrer R, Martin-Loeches I, Phillips G, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med 2014;42:1749–55. PMID 24717459


Lepine S, Lawton B, Geller S, et al. Severe maternal morbidity due to sepsis: the burden and preventability of disease in New Zealand. Aust NZ Obstet Gynaecol 2018; Feb 20. doi: 10.1111/ajo.12787. PMID: 29460453


Septimus EJ, Coopersmith CM, Whittle J, et al. Sepsis National Hospital Inpatient Quality Measure (SEP-1): multistakeholder work group recommendations for appropriate antibiotics for the treatment of sepsis. Clin Infect Diseases 2017;65(9):1565–9. PMID 29048513


RCOG Green-top guideline No. 64b. April 2012. Bacterial sepsis following pregnancy.


World Health Organization. WHO recommendations for prevention and treatment of maternal peripartum infections. World Health Organization, Geneva.;jsessionid=4EDFC6D24BE2799DDE0C36218D24F89A?sequence=1


Heine RP, Puopolo KM, Beigi R, et al., and the American College of Obstetricians & Gynecologists’ Committee on Obstetric Practice. ACOG Committee Opinion no. 712. August 2017. Intrapartum management of intraamniotic infection. Obstet Gynecol 2017;130 (2):e95-e100. PMID 28742677


Marshall JC, Maier RV, Jimenez M, et al. Source control in the management of severe sepsis and septic shock: an evidence-based review. Crit Care Med 2004;32[11 Suppl.]:S513–26. PMID 15542959


Marik P, Bellomo R. A rational approach to fluid therapy in sepsis. Br J Anaesthesia 2016;116(3):339–49. PMID 26507493


Lee CWC, Kory PD, Arntfield RT. Development of a fluid resuscitation protocol using inferior vena cava and lung ultrasound. J Crit Care 2016;31:96–100. PMID 26475100


Monnet X, Marik P, Teboul J-L. Passive leg raising for predicting fluid responsiveness: a systematic review and meta-analysis. Intens Care Med 2016 Jan 29 [Epub 2016 Jan 29].doi:10.1007/s00134–015–4134–1. PMID 26825952


Marques NR, Martinello C, Kramer GC, et al. Passive leg raising during pregnancy. Am J Perinatol 2015 Mar;32(4):393–8. PMID 25241109


Rivers E, Nguyen B, Havstad S, et al., for the Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. New Engl J Med 2001;345:1368–77. PMID 11794169


ProCESS Investigators, Yealy DM, Kellum JA, et al. A randomized trial of protocol-based care for early septic shock. New Engl J Med 2014;370:1683–93. PMID 24635773


ARISE Investigators; ANZICS Clinical Trials Group, Peake SL, et al. Goal-directed resuscitation for patients with early septic shock. New Engl J Med 2014;371:1496–1506. PMID 25272316


Mouncey PR, Osborn TM, Power S, et al. ProMISe Trial Investigators. Trial of early, goal-directed resuscitation for septic shock. New Engl J Med 2015;372:1301–11. PMID 25776532


Ngan Kee WD, Lee SWY, Ng FF, et al. Randomized double-blinded comparison of norepinephrine and phenylephrine for maintenance of blood pressure during spinal anesthesia for cesarean delivery. Anesthesiology 2015;122:736–45. PMID 25635593


Minzter BH, Johnson RF, Paschall RL, et al. The diverse effects of vasopressors on the fetoplacental circulation of the perfused human placenta. Anesth Analg 2010;110:857–862. PMID 20032025


Surgers L, Valin N, Carbonne B, et al. Evolving microbiological epidemiology and high fetal mortality in 135 cases of bacteremia during pregnancy and postpartum. Eur J Clin Microbiol Infect Dis 2013;32:107–113. PMID 22907333


Surgers L, Bleibtreu A, Burdet C, et al., on behalf on the COLIBAFI Group. Escherichia coli bacteraemia in pregnant women is life-threatening for fetuses. Clin Microbiol Infect 2014;20:O1035–41. PMID 24979689


Winters BD, Eberlein M, Leung J, et al. Long-term mortality and quality of life in sepsis: a systematic review. Crit Care Med 2010;38:1276–83. PMID 20308885


Annane D, Sharshar T. Cognitive decline after sepsis. Lancet Respir Med 2015;3:61–69. PMID 25434614


Hinton L, Locock L, Knight M. Support for mothers and their families after life-threatening illness in pregnancy and childbirth: a qualitative study in primary care. Br J General Pract 2015; doi:10.3399/bgjp15X686461. PMID 26324492


Marshall J. Sepsis definitions: a work in progress. Crit Care Clinics 2018;34:1–14. PMID 29149932

Online Study Assessment Option
All readers who are qualified doctors or allied medical professionals can now automatically receive 2 Continuing Professional Development credits from FIGO plus a Study Completion Certificate from GLOWM for successfully answering 4 multiple choice questions (randomly selected) based on the study of this chapter.
Medical students can receive the Study Completion Certificate only.


(To find out more about FIGO’s Continuing Professional Development awards programme CLICK HERE)